Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.


1. Explore the rationale for immunotherapy in head and neck cancers given tumor immune escape mechanisms.

2. Outline findings from clinical trials for immune checkpoint inhibitors in the treatment of locally advanced and recurrent/metastatic head and neck cancer.

3. Examine novel approaches to integrate immune checkpoint inhibitors into optimal sequencing with other modalities and discuss the role of biomarkers in clinical decision making.

4. Identify multidisciplinary strategies to prevent, anticipate, and manage immune-related adverse events in head and neck cancer patients receiving immunotherapy.

Target Audience

This activity is designed to meet the educational needs of Medical Oncologists, Radiation Oncologists, Head and Neck Surgeons, and related healthcare professionals attending the 2018 Multidisciplinary Head and Neck Cancers Symposium.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Adrienne Matson, PharmD, BCPS has no relevant financial relationships to disclose in relation to the content of this activity.

Ezra Cohen, MD-has disclosed that he is a consultant for AstraZeneca, Bristol-Myers Squibb, Eisai, Merck, and Pfizer

Maura L. Gillison, MD, PhD-has disclosed that she is a consultant for Aspyrian, Bristol-Myers Squibb, Celgene, EMD Serono, and Merck. She also receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Kyowa, Merck, and Roche.

David Raben, MD-has disclosed that is a consultant for AstraZeneca, Genentech, and Merck.

CME Reviewer:
Susan H. Scher, MD-has no relevant financial relationships to disclose in relation to the content of this activity.